How to Buy a Substance Abuse Treatment Center in 2026

Substance use disorder (SUD) treatment is one of the most politically charged, regulatorily complex, and operationally demanding segments of healthcare M&A. It is also one of the most opportunistic right now. The 2017-2020 bubble, when PE firms like Bain Capital, KKR, and Acadia were paying 12-15x EBITDA for residential platforms, has fully deflated. Federal and state enforcement actions against patient brokering, urine drug testing fraud, and insurance billing schemes in South Florida and Southern California blew up several marquee platforms and scared the institutional capital out of the space.

What is left is a fragmented market of legitimate operators trading at 5-8x EBITDA — roughly half of peak — and a smaller set of well-run residential and PHP/IOP platforms that still attract strategic interest. If you can navigate the regulatory complexity, SUD treatment is a mission-driven business with genuine demand and reasonable entry multiples. If you cannot, it is a fast way to lose your license and your investment. Here is how to do it right.

Understand What Level of Care You Are Buying

The ASAM (American Society of Addiction Medicine) levels of care determine everything about how the business is regulated, reimbursed, and valued. You need to know exactly which levels the target operates:

ASAM Level 3.7 (Medically Monitored Inpatient) and 3.5 (Clinically Managed High-Intensity Residential). Residential treatment. Highest per-diem rates ($800-$1,500/day commercial), highest regulatory burden, real estate and licensed beds.
ASAM Level 2.5 (Partial Hospitalization / PHP). 20+ hours/week of structured programming. Reimbursement typically $350-$650/day commercial.
ASAM Level 2.1 (Intensive Outpatient / IOP). 9-19 hours/week. $200-$400/day commercial.
ASAM Level 1 (Outpatient) and MAT (Medication-Assisted Treatment). Office-based, Suboxone/methadone/Vivitrol programs. Lower per-visit revenue but higher census turnover and lower cost to deliver.

Most platforms combine multiple levels — a residential program with step-down PHP and IOP, or an outpatient MAT clinic network. Higher-acuity residential generates more revenue per patient but is also where the enforcement risk lives. Lower-acuity outpatient and MAT are safer acquisitions but trade at lower multiples.

Accreditation and License Transfer

Almost every legitimate SUD facility holds accreditation from either The Joint Commission (TJC) or CARF International. Most commercial payers and all state Medicaid programs require it. Accreditation does not automatically transfer in an acquisition — both TJC and CARF treat a change of ownership as a trigger for a new survey, and you need to notify them within 30 days of closing.

In practice, if you buy the operating entity (stock purchase) and keep the same license numbers, NPI, and CLIA, accreditation carries forward until the next scheduled survey. If you buy assets and set up a new operating entity, you are starting fresh — new state license application, new accreditation application, new payer contracts. The asset deal structure adds 6-12 months to your ramp and is one of the most common mistakes first-time SUD buyers make.

State licensing is the bigger problem. Every state regulates SUD facilities separately — California DHCS, Florida DCF, Pennsylvania DDAP, Texas HHSC. License transfer timelines range from 30 days (best case) to 9 months (Florida and California in bad years). Some states require the new owner to operate under the existing license for a transition period; others require a full new application. Your attorney needs to map this out in the LOI, not after signing.

Payer Mix Is the Whole Business

Payer mix determines whether an SUD facility is a good acquisition or a trap. The rough hierarchy of revenue quality is:

Commercial in-network contracts (BCBS, Aetna, Cigna, UHC): Lower per-diem rates but predictable, sustainable, and survive payer audits. The best long-term revenue.
Commercial out-of-network (OON): Higher reimbursement historically but collapsing. Most major commercial payers now cap OON SUD reimbursement at Medicare-equivalent rates or deny entirely. An OON-dependent facility is a melting ice cube.
Medicaid / Medicaid managed care: Low per-diems but stable volume and no OON risk. The backbone of any sustainable outpatient operation.
Self-pay and scholarship: Highly variable. Often the business is subsidizing the revenue.

During diligence, pull the last 36 months of revenue by payer and by CPT/HCPCS code. If the facility's EBITDA is dependent on OON commercial reimbursement, model a 50-70% reduction to those rates and see if the deal still works. It usually does not, and that is why you can buy these facilities at 4-6x EBITDA instead of 10x.

Regulatory Diligence That Actually Matters

SUD treatment has the highest regulatory risk profile of any outpatient healthcare business. The items that deserve real attention:

42 CFR Part 2 is the federal confidentiality regulation for SUD records and it is significantly stricter than HIPAA. A single unauthorized disclosure — including in a sloppy data room during your own diligence — is a federal violation. Your diligence needs to be conducted through a qualified service organization agreement and with de-identified data where possible. Every attorney in this space knows this; verify yours does.

Patient brokering / Eliminating Kickbacks in Recovery Act (EKRA).EKRA was passed in 2018 and criminalizes paying for patient referrals to SUD treatment, including common industry practices like marketing affiliate commissions and percentage-of-collections compensation for intake staff. If the target is paying outside marketers on a per-admission basis, that is a direct EKRA violation and you are buying a federal liability. Get every marketing agreement reviewed by healthcare counsel before you close.

Urine drug testing billing. The 2014-2018 UDT billing scandals (presumptive + definitive testing on every patient, every visit, billed to commercial OON at $2,000-$5,000 per specimen) produced dozens of federal indictments and hundreds of civil recoupment actions. Modern compliant programs bill UDT conservatively — typically 1-2 definitive panels per month per patient, medical necessity documented in the chart. Pull the lab billing data and compare to industry norms. Outliers are red flags.

Joint Commission or CARF survey history. Pull the last two survey reports and every Requirement for Improvement (RFI) or Opportunity for Improvement. Unresolved findings become your problem on day one.

State inspection and complaint history. FOIA the state agency for the facility's inspection and complaint file. I have seen sellers fail to disclose open state investigations that killed deals in the final week.

Valuation and Financing

SUD treatment valuations in 2026 look roughly like this:

OON-dependent residential: 3-5x EBITDA. Declining asset class; most strategic buyers will not touch it.
In-network residential with TJC/CARF and diversified payer mix: 6-8x EBITDA.
Outpatient/IOP/PHP platform with 3+ locations and in-network contracts: 7-10x EBITDA.
Office-based MAT networks (Suboxone-focused): 6-9x EBITDA; premium for scale and Medicaid managed care contracts.
Opioid treatment programs (methadone OTPs): 8-12x EBITDA. DEA-limited supply, very sticky patient base, and limited new licensing.

Financing is harder than most healthcare verticals. Traditional SBA lenders are cautious on SUD (Live Oak and Byline will do it for the right operators, many others will not). Above the SBA cap, you are looking at specialty healthcare lenders like Capital One Healthcare, White Oak, or Monroe Capital. Expect lower leverage (3.0-3.5x EBITDA vs. 4x+ in other healthcare) and tighter covenants. Real estate is often financed separately, which helps the operating company leverage math. See our SDE vs EBITDA guide for how lenders normalize addiction treatment earnings.

The People and Culture Problem

SUD treatment is run by clinicians and counselors who are in the field because they believe in the mission. Many are in recovery themselves. A buyer who walks in talking about EBITDA synergies and wage normalization will face clinician resignations within weeks. I have seen it happen. The operational playbook that works is to over-invest in the clinical leadership during the transition, keep the medical director and clinical director on long-term contracts with retention bonuses, and delay any back-office consolidation for at least 12 months.

Staffing is also a regulated input. States mandate minimum counselor-to-patient ratios (typically 1:8 to 1:12 for residential, 1:15 for PHP, 1:20 for IOP). You cannot cost-reduce your way below those ratios without losing your license. Model the labor line with that constraint in mind.

The Bottom Line

SUD treatment is a real business with real demand — overdose deaths remain near historic highs and commercial parity laws have forced payers to cover treatment at something approaching medical/surgical rates. The acquisition opportunity exists because the regulatory and operational complexity scares off generalist buyers. If you bring healthcare-specific counsel, do serious EKRA and 42 CFR Part 2 diligence, and buy facilities with in-network payer mix rather than OON schemes, you can build durable value. Run the target through our valuation calculator with a stress case on OON reimbursement compression before you commit capital.